In BRCA deficient germ-line or platinum-sensitive sporadic epithelial ovarian cancers, PARP inhibitor (Niraparib, Olaparib, and Rucaparib) maintenance therapy substantially improves progression-free survival in patients [31,32,33,34]. Here, PARP1 is linked to ovarian carcinoma.